SHIGA TOXIN MODE OF ACTION IN E. COLI O157:H7 DISEASE
Tom G. Obrig
Department of Microbiology and Immunology, University of Rochester, Box 672, 601 Elmwood Avenue, Rochester, NY 14642
Received 12/2/97 Accepted 12/8/97
TABLE OF CONTENTS:
Key words: Shiga toxin, Verotoxin, E. coli O157:H7, Vascular disease, Endothelium, Kidney, Protein synthesis
- 1. Abstract
- 2.. The Shiga toxins (Stx)-Overview.
- 2.1 Shiga toxin production by gram-negative pathogenic bacteria.
2.2 Evolution of Stxs and the "emerging pathogen", E. coli O157:H7
2.3 Stx is a vascular acting toxin.
- 3. Biochemical features of the Shiga toxins.
- 3.1 Subunit protein structure
3.2 Stx removal of a single base from 28S rRNA.
3.3 Stx is a member of the ribosome inactivating protein family.
- 4. Stx Isotypes produced by E. coli O157:H7.
5. Stx Receptors expressed on eukaryotic cells.
- 5.1 The Stx receptor is a glycosphingolipid, Gb3.
5.2 Specificity of Stx-receptor interaction.
5.3 Potential receptor-based therapeutics for EHEC disease.
- 6. Internalization and processing of Stx by eukaryotic cells.
- 6.1 Stx enters cells by receptor-mediated endocytosis.
6.2 Processing and activation of Stx in target cells.
- 7. A Role for Shiga toxins in vascular disease.
- 7.1 Evidence for Stxs' role in EHEC-associated vascular disease.
7.2 Additional bacterial factors in EHEC-associated vascular disease.
- 8. Sensitivity of human endothelial cells to Stxs.
- 8.1 Endothelial cells are the putative target of Stxs.
8.2 Host cytokine regulation of Stx-sensitivity in endothelial cells.
- 9. Acknowledgments
- 10. References
- 11. Entire manuscript
Search OMIM (Online Mendelian Inheritance in Man) to find related articles
This form requires a WWW Client such as Netscape, XMosaic, Lynx that supports fill-in forms.